NCT05683418 2026-04-22
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Totus Medicines
Phase 1 Recruiting
Clinical Trials
29 trialsNCT06126276 2026-04-22
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05564377 2026-04-21
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06997029 2026-04-21
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT04862663 2026-04-20
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT07347600 2026-04-20
reaINAVO
Hoffmann-La Roche
Recruiting
NCT07174336 2026-04-17
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04606446 2026-04-16
KAT6
Pfizer
Phase 2 Recruiting
NCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT04841148 2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT06188520 2026-04-08
CYCAD-1
AstraZeneca
Phase 1/2 Recruiting
NCT04360941 2026-04-06
PAveMenT
Royal Marsden NHS Foundation Trust
Phase 1 Recruiting
NCT06065748 2026-04-06
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT04654208 2026-03-31
SIRI
Pfizer
Recruiting
NCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06377852 2026-03-18
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06736704 2026-03-13
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06843967 2026-03-13
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT02896335 2026-03-12
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
Phase 2 Recruiting
NCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
NCT05768139 2026-03-02
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT06760637 2026-03-02
FourLight-3
Pfizer
Phase 3 Recruiting
NCT06757634 2026-02-05
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting